Compare Apple Inc (AAPL) vs Abeona Therapeutics Inc (ABEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Abeona Therapeutics Inc — how do they compare? Apple Inc trades at $313.3 (market cap $4.56T), while Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M). The key difference: Apple Inc is far larger — about 12214.7× Abeona Therapeutics Inc's market cap, and Apple Inc pays a 0.35% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AAPL | ABEO | |
|---|---|---|
Market Cap | $4.56T | $373.32M |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $7.23 |
52-Week Low | $202.38 | $4.17 |
Enterprise Value | $4.58T | $228.22M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $313.28, up 0.2% with strong technical momentum and bullish moving average signals. The company reported robust Q1 2026 earnings of $2.01 EPS, beating estimates, with revenue growth accelerating to $416.16B in 2025. Analyst consensus remains positive with 63% buy ratings and a $329.62 price target. Recent news highlights Apple's AI potential through its 2.5 billion device ecosystem and partnership with Alphabet's Gemini.
Apple demonstrates strong fundamental performance with expanding profit margins and consistent earnings beats. The stock offers upside to analyst targets but faces risks from potential Q2 earnings miss, union disputes, and regulatory pressures. Valuation multiples remain elevated, requiring sustained growth to justify current levels.
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →
